Related Experiment Video

Updated: May 9, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease

Zhiyou Cai1, M Delwar Hussain, Liang-Jun Yan

  • 11Department of Neurology, The Lu'an Affiliated Hospital of Anhui Medical University , Lu'an People's Hospital, Lu'an, Anhui Province , China.

The International Journal of Neuroscience
|August 13, 2013
PubMed

Insights

Microglia play a dual role in Alzheimer's disease (AD) pathogenesis, contributing to both disease progression and potential clearance of amyloid plaques (Aβ). Targeting the inflammatory cycle involving microglia and Aβ offers a promising therapeutic strategy for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Microglia, the brain's immune cells, exhibit dual roles in Alzheimer's disease (AD) pathogenesis.
  • Microglia contribute to AD by releasing inflammatory mediators that promote beta-amyloid (Aβ) production and accumulation.
  • Conversely, microglia can also be beneficial by producing anti-Aβ antibodies and aiding in plaque clearance.

Purpose of the Study:

  • To elucidate the complex roles of microglia in Alzheimer's disease (AD) pathogenesis.
  • To understand the interplay between microglia, neuroinflammation, and beta-amyloid (Aβ) accumulation in AD.
  • To explore therapeutic strategies targeting microglial activation and the inflammatory cycle in AD.

Main Methods:

  • Review of basic molecular biology evidence.
  • Analysis of the mechanisms of microglia activation and inflammatory mediator release.
  • Examination of the role of beta-amyloid (Aβ) in inducing microglia activation and neuroinflammation.

Main Results:

  • Microglia contribute to AD pathogenesis through the release of inflammatory cytokines, complement components, chemokines, and free radicals, exacerbating Aβ production and deposition.
  • A vicious cycle exists between Aβ accumulation, activated microglia, and inflammatory mediators, which enhances both Aβ deposition and neuroinflammation.
  • Microglia also play a protective role by generating anti-Aβ antibodies and promoting amyloid plaque clearance.

Conclusions:

  • Inhibiting the inflammatory cycle involving microglia and Aβ represents a promising therapeutic approach for halting AD progression.
  • Targeting microglial activation and neuroinflammation presents a potential therapeutic avenue for AD, despite previous setbacks with anti-inflammatory drugs.

More Related Videos

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...